ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet Oncol · 2026-07-03

Post hoc analysis of PACIFIC (660 patients, unresectable stage III NSCLC after chemoradiotherapy): with durvalumab, baseline PPI use was associated with shorter median PFS (9·4 vs 17·2 months; HR 1·57) and OS (33·0 vs 57·9 months; HR 1·66); no association with placebo.

Secondary analysisn = 660
Brunetti et al. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.